ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Health Care · Nasdaq
A clinical-stage RNA interference biotech transitioning to commercial revenue through targeted gene-silencing therapeutics.
What ARROWHEAD PHARMACEUTICALS, INC. does
Arrowhead Pharmaceuticals is a biopharmaceutical company that develops RNA interference (RNAi) and other gene-modulating therapies targeting oncology, hepatic, and other disease areas. The company operates through research, development, and commercialization of its own drug candidates as well as through collaborations with strategic partners. Revenue comes from upfront payments, milestones, royalties, and commercial sales of approved therapies.
Themes: []
Fundamentals
- Price$76.40 as of 2026-07-10 close
- Market cap$10.8B as of 2026-07-12
- 1-year return+305.1% as of 2026-07-10 close
- Net margin-48.4% as of 2026-07-12
- Gross margin+100.0% as of 2026-07-12
- ROE-55.5% as of 2026-07-12
- Debt / equity2.06 as of 2026-07-12
- Revenue growth (YoY)+14.1% as of 2026-07-12
- Revenue CAGR (3y)+50.5% SEC XBRL
- Beta1.28 as of 2026-07-12
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.